LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABII - News), a fully integrated biotechnology company, today announced it has initiated enrollment in its Phase II clinical trial to evaluate the efficacy and safety of Coroxane™ for the prevention and reduction of restenosis following revascularization of the superficial femoral artery (SFA).
